By Fineline Cube 
Swiss pharmaceutical company Novartis (NYSE: NVS) announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its drug Scemblix (asciminib). The approval is for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP).
Scemblix: A Breakthrough in CML Treatment
Scemblix is the world’s first molecule Specifically Targeting the ABL Myristoyl Pocket (STAMP inhibitor). It has demonstrated the ability to double the deep remission rate and halve the risk of adverse event-related discontinuation, thus delaying disease progression. The drug was granted accelerated approval in the United States for this indication in October of last year.-Fineline Info & Tech